Pembrolizumab
Pembrolizumab is an anticancer medication used to treat various types of cancer, including melanoma, lung cancer, Hodgkin lymphoma, and certain head and neck cancers. It belongs to the immune checkpoint inhibitor class of drugs, specifically programmed cell death protein 1 (PD-1) inhibitors. It works by blocking the PD-1 receptor on T-cells, preventing cancer cells from suppressing the immune response and allowing the immune system to recognize and attack tumour cells. It is administered through intravenous infusion, usually every 3 or 6 weeks, depending on the treatment regimen. Common side effects include fatigue, nausea, itching, rash, and diarrhoea. Serious adverse effects may include immune-related inflammation of the lungs, liver, intestines, and thyroid gland. It should be administered under the supervision of an oncologist with regular monitoring.
Pembrolizumab was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Pembrolizumab, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Pembrolizumab from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Pembrolizumab, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
